AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32147068
Drug: Edible glucose
RxNorm normalized name: edible oyster preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edible glucose 30% (2 ml, n = 40)
Trial: 39223470
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia
Trial: 33326140
Drug: Athlete Biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Athlete Biological Passport
Trial: 35298833
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 2% (5 g/daily) for 24 weeks
Trial: 34106922
Drug: Levo-Praziquantel (L-PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levo-Praziquantel (L-PZQ) ODT 150 mg
Trial: 34106922
Drug: Racemate Praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Racemate Praziquantel (Rac-PZQ) ODT 150 mg
Trial: 34106922
Drug: PZQ 600
RxNorm normalized name: L-PZQ
DrugBank: (R)-Praziquantel (DB11749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZQ 600 mg formulation (PZQ-Cesol) crushed and dispersed in water
Trial: 34446332
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT), performed once a week for 12 weeks on quadriceps femoris muscles.
Trial: 32318831
Drug: Air/water spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air/water spray (control group)
Trial: 34229861
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (1.5 mg.kg-1 bolus over 3 minutes, followed by continuous infusion at 2 mg.kg-1.h-1)
Trial: 34229861
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline solution (control group)
Trial: 34564685
Drug: Intra-alveolar administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-alveolar administration of dexamethasone 4 mg
Trial: 34564685
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of dexamethasone
Trial: 32111230
Drug: Ringer's acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's acetate solution
Trial: 38152462
Drug: Dextromethorphan (DXM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DXM) 400 mg/70 kg
Trial: 36227615
Drug: Capecitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1000 mg/m2 twice daily for 14 days every 3 weeks for 8 cycles)
Trial: 36227615
Drug: Observation following
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation following CCRT (100 mg/m2 cisplatin every 3 weeks for 2 to 3 cycles)
Trial: 35366853
Drug: Beraprost sodium
RxNorm normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beraprost sodium (BPS) 60 μg/day and aspirin 100 mg/day
Trial: 34533102
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training (RT) twice-weekly for 10 weeks
Trial: 34399432
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (OACs)
Trial: 35677972
Drug: Ribavirin aerosol
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin aerosol (50 mg/ml, 10 ml total volume)
Trial: 35677972
Drug: Ribavirin aerosol
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin aerosol (50 mg/ml, 20 ml total volume)
Trial: 35677972
Drug: Ribavirin aerosol
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin aerosol (100 mg/ml, 10 ml total volume)
Trial: 35677972
Drug: Ribavirin aerosol
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin aerosol (100 mg/ml, 20 ml total volume)
Trial: 34535979
Drug: Telemonitoring intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemonitoring intervention with four daily short text messages for 30 days
Trial: 34665055
Drug: Aggressive heating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive heating with three different heaters (compressed-air blower heater, intravenous fluid heating, heating bed)
Trial: 35674747
Drug: Low-dose triple
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose triple combination therapy
Trial: 33097936
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (∼4 g/d)
Trial: 33097936
Drug: ALA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA supplementation (∼4 g/d)
Trial: 32029008
Drug: Ibuprofen sustained-release
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen sustained-release capsules
Trial: 35576498
Drug: Rapid Syllable
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Syllable Transition Treatment (ReST)
Trial: 35576498
Drug: Blended intervention
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended intervention (combination of ReST and AAC)
Trial: 32651146
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (Control group, n = 36)
Trial: 32349074
Drug: Calibrated esophageal
RxNorm normalized name: CALIBRATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calibrated esophageal pressure measurements during pneumoperitoneum-Trendelenburg and PEEP administration
Trial: 32932396
Drug: Buffered and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered and nonbuffered saline solutions
Trial: 35731881
Drug: Conversations focusing
RxNorm normalized name: ficusin
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversations focusing on disagreement (e.g., why each supports their own party)
Trial: 32845114
Drug: Roflumilast cream
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast cream 0.5%
Trial: 36745371
Drug: Roflumilast cream
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast cream 0.15%
Trial: 34645147
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy + glutamine
Trial: 34645147
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy + glutamine
Trial: 35130547
Drug: IQP-LU-104 high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IQP-LU-104 high dose (104HD)
Trial: 35130547
Drug: IQP-LU-104 low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IQP-LU-104 low dose (104LD)
Trial: 32732353
Drug: Denosumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (all dose groups)
Trial: 35385827
Drug: Vi polysaccharide
RxNorm normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi polysaccharide (ViPS) vaccine
Trial: 34549356
Drug: Succinylated gelatin
RxNorm normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylated gelatin (4%) (GEL)
Trial: 34549356
Drug: Compound sodium
RxNorm normalized name: SODIUM CHLORIDE 6 g in 1 L / SODIUM LACTATE 3.22 g in 1 L / POTASSIUM CHLORIDE 400 mg in 1 L / CALCIUM CHLORIDE 270 mg in 1 L INTRAVENOUS INJECTION, SOLUTION [COMPOUND SODIUM LACTATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound sodium lactate (CSL)
Trial: 35077606
Drug: MZ-004 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MZ-004 900 μg
Trial: 35077606
Drug: MZ-004 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MZ-004 1200 μg
Trial: 35077606
Drug: MZ-004 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MZ-004 (both doses)
Trial: 33278280
Drug: Early pregnancy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early pregnancy loss treatment
Trial: 32482490
Drug: CVT-301 (levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVT-301 (levodopa inhalation powder) 84 mg (+25 mg of oral carbidopa)
Trial: 32482490
Drug: Oral carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbidopa/levodopa (25/100 mg)
Trial: 33836658
Drug: Lidocaine coinfusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine coinfusion (1 mg/kg bolus followed by 2 mg/kg/h infusion)
Trial: 33836658
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (equivalent volume bolus and infusion)
Trial: 33393600
Drug: Twin mix
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twin mix (2% lidocaine with 1:200,000 epinephrine and 1 mL of 4 mg dexamethasone)
Trial: 36057658
Drug: Combined complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined complex decongestive therapy (CDT) with therapeutic ultrasound
Trial: 36057658
Drug: Combined complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined complex decongestive therapy (CDT) with faradic current
Trial: 36057658
Drug: Complex decongestive
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex decongestive therapy (CDT) alone (Control)
Trial: 34289784
Drug: Calcipotriol 0.005%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 0.005% cream
Trial: 34289784
Drug: Topical corticosteroid;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid; Clobetasone butyrate 0.05% cream
Trial: 36176149
Drug: Robot-Assisted Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-Assisted Therapy protocol with gesture training
Trial: 34366306
Drug: TRADE: worksite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRADE: worksite PA education with a manual plus American College of Sports Medicine guided PA prescription
Trial: 34570799
Drug: Self-collected rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-collected rectal specimens
Trial: 32652243
Drug: 5 tablets
RxNorm normalized name: Xpovio 100 MG Weekly Dose Carton Pack, 4 Blister Cards, 5 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 tablets of 5‐mg oxycodone
Trial: 32652243
Drug: 10 tablets
RxNorm normalized name: ALLANTOIN 0.11 in 600 mg VAGINAL TABLET [Jilgyungyi (10 Tablets)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 tablets of 5‐mg oxycodone
Trial: 32613345
Drug: Laparoscopic partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic partial mesorectal excision (L‐PME)
Trial: 35275166
Drug: Multicomponent safety
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent safety intervention including education on fall prevention, home medication review, home safety assessment, and occupational therapy home visits.
Trial: 33891508
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment for 8 weeks
Trial: 35536547
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cell vaccine (DCVAC)
Trial: 33483965
Drug: Intermittent serial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent serial casting in conjunction with occupational therapy and botulinum neurotoxin A (BoNT‐A)
Trial: 33483965
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving BoNT‐A and occupational therapy without casting
Trial: 34561890
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) > 14 ng/l
Trial: 34561890
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) ≤ 14 ng/l
Trial: 37125529
Drug: ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 5 mg
Trial: 34166970
Drug: Intensive PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive PCA treatment (3 hours/day, 4 days/week for 2.5 weeks)
Trial: 34166970
Drug: Standard PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PCA treatment (1 hour/day, 3 days/week for 10 weeks)
Trial: 36001989
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg daily alone
Trial: 33785069
Drug: Remifentanil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (3 to 4 μg/kg)
Trial: 33785069
Drug: Rapid-onset paralytic
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-onset paralytic agents (succinylcholine or rocuronium 1 mg/kg)
Trial: 32390164
Drug: Thiamidol applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamidol applied four times daily
Trial: 32390164
Drug: Thiamidol applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamidol applied two times daily
Trial: 32956479
Drug: Cyclopentolate 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclopentolate 1% as spray
Trial: 32737814
Drug: Gambling Symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gambling Symptom Assessment Scale (G-SAS) scores
Trial: 35915198
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg monotherapy twice daily with a meal
Trial: 35915198
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg monotherapy twice daily in a modified fasting state
Trial: 35915198
Drug: Abemaciclib 200
RxNorm normalized name: abemaciclib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib 200 mg monotherapy twice daily without regard to food
Trial: 34880615
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray plus newly initiated antidepressant
Trial: 37792613
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray
Trial: 33325785
Drug: Adjuvanted Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted Escherichia coli adhesin vaccine
Trial: 33507550
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g glucose drink
Trial: 34664858
Drug: Neurofeedback combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurofeedback combined with acupuncture treatment
Trial: 34514678
Drug: PEG‐IFN‐? monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐? monotherapy
Trial: 34514678
Drug: PEG‐IFN‐? plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐? plus NA de novo combination
Trial: 34514678
Drug: NA monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA monotherapy
Trial: 32432553
Drug: Tablet intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet intervention consisting of information about IPV and safety behaviors during prenatal care.
Trial: 32432553
Drug: Tablet intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet intervention (video to promote safety behaviors delivered on a tablet).
Trial: 32432553
Drug: Tablet intervention.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet intervention.
Trial: 35031147
Drug: Intradermal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal administration using Immucise™
Trial: 35031147
Drug: Standard subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard subcutaneous (SC) administration of seasonal influenza vaccine
Trial: 34690144
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg bid (24-week unblinded active-dose therapeutic trial)
Trial: 35560363
Drug: mnemoPQQ® (21.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mnemoPQQ® (21.5 mg/day)
Trial: 33231105
Drug: Combination doses
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination doses of ketamine and dexmedetomidine, given intranasally
Trial: 33231105
Drug: Optimal combination
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal combination therapy
Trial: 32563171
Drug: Perampanel (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (up to 8 mg/day during double-blind phase, up to 12 mg/day during open-label extension phase)
Trial: 35045098
Drug: 12% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% carbohydrate beverage (250 ml bolus containing 30 g maltodextrin and 30 g sucrose)
Trial: 32907375
Drug: Aquatic high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic high intensity interval training (10 weeks, twice weekly, consisting of 10 one-minute exercise intervals with one-minute rest, achieving ⩾80% of peak heart rate)
Trial: 36126505
Drug: Adhesive application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive application after HF surface treatment
Trial: 36126505
Drug: Adhesive application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive application after MEP surface treatment
Trial: 33587824
Drug: Fitusiran 50
RxNorm normalized name: Fitusiran
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran 50 mg
Trial: 33587824
Drug: Fitusiran 80
RxNorm normalized name: Fitusiran
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fitusiran 80 mg
Trial: 34607519
Drug: Pertuzumab injection
RxNorm normalized name: pertuzumab Injection
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab injection (5 mg/kg)
Trial: 34607519
Drug: Perjeta® (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perjeta® (5 mg/kg)
Trial: 32463456
Drug: Osimertinib, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib, 80 mg daily and Bevacizumab, 15 mg/kg once every 3 weeks
Trial: 36443896
Drug: Group-format multi-component
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-format multi-component programme based on cognitive behavioural therapy and positive psychology (6 sessions, 10 weeks)
Trial: 32583557
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of therapy (IC)
Trial: 33686559
Drug: ECMO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECMO treatment
Trial: 34128810
Drug: Passive controls
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive controls (no treatment or waitlist)
Trial: 32829060
Drug: Intravenous glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycerol and dexamethasone
Trial: 35916920
Drug: Combination arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination arm (RE + sorafenib)
Trial: 36135935
Drug: MH‐SR (500 mg/tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MH‐SR (500 mg/tablet)
Trial: 36135935
Drug: Glucophage®‐XR (500 mg/tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucophage®‐XR (500 mg/tablet)
Trial: 34805718
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus investigational agent (A)
Trial: 32768001
Drug: ECCO2R therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ECCO2R therapy for ARDS